Emerging Metabolic Therapies in Pulmonary Arterial Hypertension.
about
Mitochondrial dysfunction and pulmonary hypertension: Cause, Effect or Both.Effects of human relaxin-2 (serelaxin) on hypoxic pulmonary vasoconstriction during acute hypoxia in a sheep model.Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice.Mitochondrial metabolism in pulmonary hypertension: beyond mountains there are mountainsAlpha-enolase regulates the malignant phenotype of pulmonary artery smooth muscle cells via the AMPK-Akt pathway
P2860
Emerging Metabolic Therapies in Pulmonary Arterial Hypertension.
description
2017 nî lūn-bûn
@nan
2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Emerging Metabolic Therapies in Pulmonary Arterial Hypertension.
@ast
Emerging Metabolic Therapies in Pulmonary Arterial Hypertension.
@en
type
label
Emerging Metabolic Therapies in Pulmonary Arterial Hypertension.
@ast
Emerging Metabolic Therapies in Pulmonary Arterial Hypertension.
@en
prefLabel
Emerging Metabolic Therapies in Pulmonary Arterial Hypertension.
@ast
Emerging Metabolic Therapies in Pulmonary Arterial Hypertension.
@en
P2860
P356
P1476
Emerging Metabolic Therapies in Pulmonary Arterial Hypertension.
@en
P2093
Lloyd D Harvey
Stephen Y Chan
P2860
P356
10.3390/JCM6040043
P577
2017-04-04T00:00:00Z